

2 **SARS-CoV-2 Omicron variant: exploring healthcare**
3 **workers' awareness and perception of vaccine**
4 **effectiveness: a national survey during the first week**
5 **of WHO variant alert**

6 Mohamad-Hani Temsah^{a,b,c*}, Fadi Aljamaan^{a,d*}, Shuliweeh Alenezi^{a,e}, Khalid Alhasan^{a,b},
7 Abdulkarim Alrabiaah^{a,b}, Rasha Assiri^f, Rolan Bassrawi^b, Ali Alhaboob^{a,b}, Fatimah Alshahrani
8^{a,e}, Mohamad Alarabi^{a,d}, Ali Alaraj^{h,i}, Nasser S Alharbi, Rabih Halwani^{j,k}, Amr Jamal^l, Ayman
9 Al-Eyadhy^{a,b}, Naif AbdulMajeed^{b,m}, Lina Alfarranⁿ, Wafa Almashdali^o, Fahad Al-Zamil^{a,b}, Mazin
10 Barry^{a,e,p}, Ziad A. Memish^{q,r}, Jaffar A. Al-Tawfiq^{s,t,u} and Sarah Alsubaie^{a,b}

- 11 a. College of Medicine, King Saud University, Riyadh11362, Saudi Arabia
12 b. Pediatric Department, King Saud University Medical City, King Saud University,
13 Riyadh11362, Saudi Arabia
14 c. Prince Abdullah Ben Khaled Celiac Disease Research Chair, Department of
15 Pediatrics, Faculty of Medicine, King Saud University, Riyadh11362, Saudi Arabia
16 d. Critical Care Department, King Saud University Medical City, King Saud
17 University, Riyadh11362, Saudi Arabia
18 e. Department of Psychiatry, College of Medicine, King Saud University Medical City,
19 King Saud University, Riyadh11362, Saudi Arabia
20 f. Department of Basic Medical Sciences, College of Medicine, Princess Nourah bint
21 Abdulrahman University, Riyadh 11564, Saudi Arabia
22 g. Division of Infectious Diseases, Department of Internal Medicine, King Saud
23 University Medical City, King Saud University, Riyadh11362, Saudi Arabia
24 h. Department of Medicine, College of Medicine, Qassim University, Qassim51452,
25 Saudi Arabia
26 i. Dr. Sulaiman Al Habib Medical Group, Riyadh11643, Saudi Arabia
27 j. Sharjah Institute of Medical Research, University of Sharjah, Sharjah27272, United
28 Arab Emirates
29 k. Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah
30 27272, United Arab Emirates
31 l. Department of Family and Community Medicine, King Saud University Medical
32 City, Riyadh 11362, Saudi Arabia
33 m. Pediatric nephrology department, Prince Sultan Military Medical City,
34 Riyadh11159, Saudi Arabia
35 n. Department of Ob-Gyn, Dr. Abdul Rahman Al Mishari Hospital, Riyadh12241,
36 Saudi Arabia
37 o. Department of Ob-Gyn, Dr. Fatina Imran Medical Complex, Doha233, Qatar
38 p. Division of Infectious Diseases, Faculty of Medicine, University of Ottawa K1H
39 8M5, Canada
40 q. King Saud Medical City, Ministry of Health & Alfaisal University, Riyadh11533,
41 Saudi Arabia
42 r. Hubert Department of Global Health, Emory University, Atlanta, Georgia30322,
43 USA
44 s. Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco
45 Healthcare, Dhahra34465, Saudi Arabia
46 t. Infectious Disease Division, Department of Medicine, Indiana University School of
47 Medicine, Indianapolis, IN46202, USA
48 u. Infectious Disease Division, Department of Medicine, Johns Hopkins University
49 School of Medicine, Baltimore, MD21218, USA

51 *These authors contributed equally to this research.

52 * Correspondence to:

53 Mohamad-Hani Temsah; mtemsah@ksu.edu.sa P.O. Box 2925 (Internal Code 34).
54 Riyadh, 11461; Saudi Arabia
55 Author emails and ORCID IDs:
56 Mohamad-Hani Temsah (MHT): PO BOX 2925, Riyadh 11461, Saudi Arabia
57 mtemsah@ksu.edu.sa (<https://orcid.org/0000-0002-4389-9322>)
58 Fadi Aljamaan: PO BOX 2925, Riyadh 11461, Saudi Arabia faljamaan@ksu.edu.sa
59 (<https://orcid.org/0000-0001-8404-6652>)
60 Shuliweeh Alenezi: PO BOX 7747, Riyadh, 13321
61 salenizi@ksu.edu.sa (<https://orcid.org/0000-0002-7049-0960>)
62 Khalid Alhasan: PO BOX 2925, Riyadh 11461, Saudi Arabia kalhasan@ksu.edu.sa
63 (<https://orcid.org/0000-0002-4291-8536>)
64 Abdulkarim Alrabiaah alrabiaah@KSU.EDU.SA
65 Rasha Assiri raassiri@pnu.edu.sa <https://orcid.org/0000-0001-8946-4618>
66 Rolan Bassrawi rkbassrawi@ksu.edu.sa , <https://orcid.org/0000-0001-7373-1531>
67 Ali Alhaboob (AAH): PO BOX 2925, Riyadh 11461, Saudi Arabia drhboob@gmail.com
68 (<https://orcid.org/0000-0003-2126-7874>)
69 Fatimah Alshahrani : Falshahrani1@ksu.edu.sa <https://orcid.org/0000-0002-4646-7488>
70 Mohamad Alarabi : PO BOX 2925, Riyadh 11461, Saudi Arabia malarabi@ksu.edu.sa
71 (<https://orcid.org/0000-0001-5439-6109>)
72 Ali Alaraj (AAA): PO BOX 12471, Riyadh, Saudi Arabia al_araj@hotmail.com
73 (<http://orcid.org/0000-0002-7706-2328>) Naser S Alharbi nsalharbi@ksu.edu.sa
74 Rabih Halwani: rhalwani@sharjah.ac.ae
75 Amr Jamal amrjamal@ksu.edu.sa
76 Ayman AL-Eyadhy aleyadhy@ksu.edu.sa
77 Naif Abdulmajeed Dr. naifq@gmail.com
78 Lina Alfara Lalfarra19811@gmail.com
79 Wafa almashdali Almashdali@gmail.com
80 Fahad Al-Zamil fzamil@KSU.EDU.SA
81 Mazin Barry mbarry@ksu.edu.sa (<https://orcid.org/0000-0003-2274-007X>)
82 Ziad Memish zmemish@yahoo.com <http://orcid.org/0000-0002-5099-0714>
83 Jaffar A. Al-Tawfiq jaltawfi@yahoo.com (<https://orcid.org/0000-0002-5752-2235>)
84 Sarah Al-Subaie salsubaie@ksu.edu.sa (ORCID ID: <https://orcid.org/0000-0002-3128-5921>)

85 **Keywords:** COVID-19 vaccine; SARS-CoV-2 Omicron variant; healthcare
86 workers' perceptions; SARS-CoV-2 variants

88 **Abstract:** Background: As the SARS-CoV2 Omicron variant spreads in several
89 countries, healthcare workers' (HCWs) perceptions and worries regarding
90 vaccine effectiveness and boosters warrant reassessment.

91 Methods: An online questionnaire among HCWs in Saudi Arabia (KSA) was
92 distributed from Dec 1st to 6th 2021 to assess their perceptions, vaccine
93 advocacy to the Omicron variant, and their perception of the effectiveness of
94 infection prevention measures and vaccination to prevent its spread, their
95 Omicron variant related worries in comparison to the other variants, and their
96 agreement with mandatory vaccination in general for adults.

97 Results: Among the 1285 HCW participants , two-thirds were female, 49.8 %
98 were nurses, 46.4% were physicians, and 50.0% worked in tertiary care
99 hospitals. 66.9% considered vaccination to be the most effective way to prevent
100 the spread of the Omicron variant and future variants. The respondents
101 however perceived social distancing (78.0%), universal masking (77.8%), and
102 avoiding unnecessary travel (71.4%) as slightly superior to vaccination to
103 prevent the spread of SARS-CoV-2 variants. HCWs aging 55 or older agreed
104 significantly with vaccine ineffectiveness to control Omicron spread, while those
105 who believed in non-pharmacological infection prevention measures agreed
106 significantly with vaccination for that purpose. Male HCWs had a significant
107 agreement with mandatory vaccination of all eligible adult populations. On

108 the other hand, unwilling HCWs to receive the vaccine had strong
109 disagreements with mandatory vaccination.

110 Conclusions: The current study in the first week of Omicron **showed that** only
111 two-thirds of HCWs felt that vaccination was the best option to prevent the
112 spread of the **Omicron** variant, indicating the need for further motivation
113 campaigns for vaccination and booster dose. HCWs had a strong belief in
114 **infection prevention measures to contain the spread of SARS-CoV-2**
115 **variants** that should be encouraged and augmented.

116 **1. Introduction:**

117 The B.1.1.529 variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
118 was first reported to the World Health Organization (WHO) from South Africa on November 26,
119 2021 [1]. This emerging variant was named Omicron and designated as a variant of concern
120 (VOC). This variant has more than 30 mutations on its spike protein. And similar to the Alpha
121 variant, it is associated with an S-gene target failure on a specific PCR assay due to the presence of
122 69–70 deletions [2]. Preliminary evidence suggests an increased risk of reinfection with this variant
123 and high contagiousness [3,4]. The Omicron variant had been reported in 110 countries across all
124 six WHO regions as of December 22, 2021[5]. [1,2]In addition, the B.1.1.529 variant was thought to
125 have a higher transmissibility rate than other circulating variants [3,6,7]. More concern has arisen
126 from the questionable whether current vaccines provide adequate protection against this variant [8].
127 A recent study showed a 41-fold decline of the geometric mean titer (GMT) inverse of the plasma
128 dilution required for 50% reduction in infection (FRNT50) with Omicron compared to previous
129 infection with the wild-type virus, with a three-fold reduction in FRNT50 with the mRNA vaccine
130 BNT162b2[9]. However, it is likely that previous infection followed by vaccination, or a booster
131 dose for those completing their primary series, will likely increase neutralization levels that would
132 confer the needed protection against severe disease from the emerging Omicron variant [10]A
133 recent study showed that even with Omicron, the rate of hospitalization was highest among
134 unvaccinated and lowest among those who received a booster dose.88% likelihood to escape
135 current vaccines[11-13].

136 As new variants emerge, HCWs must continue to serve COVID-19 and non-COVID
137 patients while still fulfilling personal commitments for their families and themselves[14-16].
138 Burnout, emotional exhaustion, mental distress, depression and psychological stress have been
139 linked to HCWs during this pandemic, and research continues to reveal high rates of infection [17].
140 In addition to patient care, HCWs must keep up with any developments in relation to emerging
141 variants and their effects on clinical presentation, management, and measures of
142 prevention—mainly vaccination and infection prevention practices[18,19]. As the Saudi Ministry of
143 Health announced the first case of Omicron variant on Dec 1st, 2021[20], we undertook this study to
144 assess HCWs' awareness about the SARS-CoV2 Omicron variant, their worry levels in relation to
145 the different SARS-CoV2 variants, their perception of the effectiveness of the current vaccines, and
146 other preventive measures to inhibit the spread of the Omicron variant or other future variants, as
147 well as to assess their agreement with mandatory vaccination of the adult population.

148 **2. Method**

149 **2.1 Data Collection**

150 This was a cross-sectional survey (Appendix 1) carried out among HCWs in Saudi Arabia
151 (KSA), conducted between Dec 1 and 6, 2021. Participants were invited via a convenience sampling
152 technique through various healthcare providers' social media platforms, such as WhatsApp,
153 Twitter, and emails.

154 HCWs were surveyed regarding their Omicron variant awareness, perceptions of the
155 effectiveness of COVID-19 vaccinations and other measures to prevent its spread and that of other
156 future variants, and their agreement with mandatory vaccination for all eligible adults. The last part
157 of the survey focused on HCWs' resilience, anxiety, and coping strategies, which was published as
158 preprint [21]. The current survey was adopted from our previously published studies, with
159 modifications related to the new Omicron variant [22-25]. The questionnaire was pilot-validated
160 and sent through the SurveyMonkey© electronic platform as described previously [22-25].

161 Participants gave consent at the beginning of the survey, were notified about the purpose of
162 the study, and participated voluntarily in the study. The Institutional Review Board at the College
163 of Medicine and King Saud University approved the study (approval 21/01039/IRB).

164 **2.2 Statistical analyses**

165 The mean and standard deviation were used to assess continuous variables (worry level for
166 example), frequency and percentage were used for categorically measured variables (agreement
167 with mandatory vaccination for example, age was analyzed as categories). The 5-point Likert score
168 was analyzed by categorical method to assess agreement versus disagreement, the participants'
169 responses were grouped into two groups: 1. Agree including agree and strongly agree responses; 2.
170 Disagree including disagree, strongly disagree and neither agree nor disagree responses. A
171 histogram and the K-S statistical test of normality were used to assess the statistical normality
172 assumption of the continuous variables, and Levene's test was used to assess the homogeneity of
173 statistical variance assumption. A multiple-response dichotomies analysis was used to analyze the
174 multiple response variables (participants' source of information for example). Pearson's correlations
175 test (r) was used to assess the correlations between metric variables. Multivariate binary logistic
176 regression analysis was used. The associations were expressed as the odds ratio and 95%
177 confidence interval. The SPSS IBM statistical analysis program (Version#21. Armonk, NY: IBM
178 Corp.) was used for the statistical data analysis. The statistical significance level (P-value) was
179 considered at 0.01 if achieved, and 0.05 if 0.01 not achieved according to the used software.

180 **3. Results:**

181 A total of 1285 HCWs completed the online survey. Table 1 shows the participants' baseline
182 characteristics. The majority (64%) were female, and 70.9% aged between 25 and 44 years. The
183 majority were expatriates (62.3%). Regarding their clinical role, 49.8% were nurses and 46.4%
184 were physicians, of whom 24% were consultants. Fifty percent worked in tertiary institutes, while
185 two-thirds worked in the outpatient department (OPD) or general wards.

Table.1: Baseline characteristics of the participating HCWs. N=1285

Variable	Frequency	Percentage
Sex		
Female	822	64.0

Male	463	36.0
Age Group		
25-34 years	434	33.8
35 to 44 years	477	37.1
45-54 years	273	21.2
≥ 55 years	101	7.9
Nationality		
Saudi	484	37.7
Expatriate	801	62.3
Clinical Role		
Consultant	319	24.8
Assistant Consultant/Fellow	74	5.8
Resident/Registrar	203	15.8
Nurse	640	49.8
Allied Health Practitioner	49	3.8
Hospital Type		
Primary Healthcare Center	338	26.3
Secondary Hospital	302	23.5
Tertiary Hospital	645	50.2
Hospital Working Area		
Intensive Care Unit (ICU)	141	11.0
Emergency Room (ER)	91	7.1
Operating Room (OR)	41	3.2
COVID-19 Isolation Ward	53	4.1
General Ward	492	38.3
Outpatient Department (OPD)	368	28.6
Non-Clinical Area	99	7.7
Geographical Region		
Riyadh City and Central Region	740	57.6
Eastern Province	71	5.5
Western Province	120	9.3
Northern Province	34	2.6
Southern Province	320	24.9

186

187 Almost all (97.9%) of the participants did not recently travel to countries where the
188 Omicron variant has been recorded. Most (71%) HCWs had not been in contact with COVID-19
189 patients during the last 3 months, while 22.3% of the HCWs had developed COVID-19 previously.

190 Regarding COVID-19 vaccination, 99.5% had received two doses, and the first dose was
191 divided equally between AstraZeneca ChAdOx1-S and Pfizer vaccines, and 75% of the second
192 dose was of the Pfizer–BioNTech COVID-19 vaccine. Regarding the booster dose, 94.1% either

193 received or planned to receive it once eligible, according to time-based criteria of the local
 194 regulations (Table 2).

Table.2: Descriptive analysis of the HCWs' experiences of COVID-19 disease, screening and immunization.

Variable	Frequency	Percentage
Have you been in contact with COVID-19 patients during the past 3 months?		
No	912	71.0
Yes	373	29.0
Were you previously diagnosed with PCR-positive COVID-19 yourself?		
No	999	77.7
Yes	286	22.3
Did you travel to any country where the Omicron variant has been recorded during the last month?		
Yes	27	2.1
No	1258	97.9
Which vaccine did you receive for your first COVID-19 vaccine shot?		
AstraZeneca ChAdOx1-S	600	46.7
Moderna	5	0.4
Pfizer-BioNTech	676	52.6
Not received	4	0.3
Which vaccine did you receive for your second COVID-19 vaccine shot?		
AstraZeneca ChAdOx1-S	296	23.0
Moderna	20	1.6
Pfizer-BioNTech	963	74.9
Not received	6	0.5
Did you receive the third (booster) COVID-19 vaccine?		
Yes	250	19.5
No: not yet eligible for it	566	44.0
No: I do not want to receive it	76	5.9
No: but I am planning to register for it	393	30.6

195 * Mean (SD)

196 Table 3 shows the participating HCWs' awareness and knowledge of the available
 197 literature concerning certain facts and queries related to the Omicron variant (key answers
 198 displayed in brackets). Almost all (93%) the participating HCWs knew that the Omicron variant
 199 was first described in South Africa; however, 81.7% believed that the Omicron variant was already
 200 reported in Saudi Arabia. Of the respondents, 66% knew that Omicron variant is more
 201 transmissible than the Delta variant, while 26.7% were not sure. The majority (71.8%) did not know
 202 that the Omicron variant spike protein has 22 mutations. Still, 56.2% expected that Omicron variant
 203 causes similar signs and symptoms to the original variant. Most (85.1%) of our cohort were aware
 204 that SARS-CoV-2 mutations are expected, while they were almost equally divided regarding their

205 opinion on whether they were unsure or whether the Omicron variant may/may not cause more
 206 severe disease compared to previous variants. About half of the participants were unsure if mRNA
 207 or vector-based vaccines are effective against the Omicron variant. At least two-thirds of them were
 208 unsure if therapeutics such as monoclonal antibodies used against previous variants might be
 209 effective against the variant.

210 The mean participants' self-rated familiarity with the Omicron and Delta variants of the
 211 SARS-CoV-2 virus was 3.24 (SD 0.95) and 3.5 (SD0.99), respectively, with strong and significant
 212 correlation between these scores $p < 0.0001$ ($t = 6.7928$, $df = 2568$). When we explored the
 213 participants' sources of information about the Omicron variant, the MOH and WHO websites were
 214 the main sources, but social networks were also used to obtain information in equal measure (about
 215 50%), followed by Official statements (41%), hospital announcements (38%), and the Center of
 216 Disease Control (CDC) and Saudi CDC websites, which were accessed almost equally (between 30
 217 and 33%), while scientific journals were lower down on the list (28.7%).

Table 3: Descriptive analysis of HCWs' awareness and knowledge of the Omicron variant.

Variable	True No. (%)	False No. (%)	Neither True/False No. (%)
The Omicron variant is more transmissible than Delta (True)	848 (66.0%)	94 (7.3)	343 (26.7)
"Omicron" is one of the letters of the Greek alphabet (True)	674 (52.5)	81 (6.3)	530 (41.2)
The Omicron virus spike protein has 22 mutations (True)	362 (28.2)	211 (16.4)	712 (55.4)
SARS-CoV2 Omicron variant signs and symptoms are the same as the original SARS-CoV-2 variant (False)	722 (56.2)	292 (22.7)	271 (21.1)
SARS-CoV-2 virus mutations are expected (True)	1094 (85.1)	23 (1.8)	168 (13.1)
The Omicron variant causes more severe disease than the original variant (False)	493 (38.4)	374 (29.1)	418 (32.6)
People who have previously had COVID-19 could become reinfected more easily with Omicron (True)	480 (37.4)	269 (20.9)	536 (41.7)
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) might be less effective against the Omicron variant (not confirmed in the literature)	376 (29.3)	258 (20.1)	651 (50.7)
COVID-19 vector-based vaccines	290 (22.6)	233	762 (59.3)

(AstraZeneca ChAdOx1-S) might be less effective against the Omicron variant (not confirmed in the literature)		(18.1)	
Therapeutics such as monoclonal antibodies might be less effective against the Omicron variant (not confirmed in the literature)	251 (19.5)	154 (12.0)	880 (68.5)
Variable	Frequency	Percentage	
To the best of your knowledge, where was the SARS-CoV-2 Omicron variant first identified?			
UK	15	1.2	
USA	16	1.2	
South Africa	1197	93.2	
China	47	3.7	
India	10	0.8	
Participants' self-rated familiarity with the Omicron variant *		3.24 (0.95)	
Participants' self-rated familiarity with the Delta variant *		3.50 (0.99)	
Participants' sources of information about the Omicron variant			
Hospital announcements (e.g., roll-ups or newsletters)	488	38.0	
Official statements or press releases from MOH (e.g., through SMS or newspapers)	527	41.0	
MOH website	647	50.4	
WHO website	662	51.5	
CDC website	395	30.7	
Saudi CDC	430	33.5	
Social networks (such as YouTube, Facebook, Twitter, WhatsApp, etc.)	633	49.3	
Scientific journals	369	28.7	
Other sources	205	16.0	

218 * Mean (SD)

219 Of the participants, 66.9% agreed with the vaccine's effectiveness to prevent the spread of
220 Omicron or other future variants, while when considering other preventive measures, such as
221 universal masking, social distancing, and avoiding unnecessary international travel, their
222 agreement was higher (77.8%, 78%, and 71.4%, respectively). Participating HCWs (82.2%) felt that
223 the COVID-19 vaccination should be mandatory for all eligible adult populations, while only 5.1%
224 disagreed (Table 4).

225 Almost half (42.7%) of the HCWs perceived that any of the current mRNA vaccines
 226 (Pfizer–BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine) would be the best COVID-19
 227 booster vaccine, while 26.9% felt that a newly developed mRNA vaccine that would better target
 228 the Omicron variant is best, and 26.2% agreed to receive any of the available vaccines as a third
 229 booster dose (Table 4).

230 Regarding the participants' perceived risk from the Omicron variant, 16.9% felt that
 231 patients with immune deficiencies are at the highest risk, followed by the elderly (14.9%), HCWs
 232 (14.1%), and then patients with chronic medical illnesses (Table 4).

233 When assessing the participants' perceptions about future perspectives of the Omicron
 234 variant locally and internationally, 57.7% agreed that it has the potential to cause a new COVID-19
 235 pandemic wave worldwide, while only 45.9% agreed that it may cause another COVID-19 wave in
 236 Saudi Arabia, and 46.1% agreed that it may cause a lockdown (Table 4). The current cohort of
 237 HCWs had the highest worry level in relation to international travel (3.19, SD 1.12), followed by the
 238 Omicron variant (2.18, SD 1.14), and their worry levels in relation to the original SARS-CoV-2 and
 239 Delta variants were comparable (1.96, SD 1.14 and 1.97 SD, 1.13, respectively), while their worry
 240 level in relation to the Alpha variant was the lowest (1.67, SD 1.1).

241

Table 4: Descriptive analysis of the HCWs' beliefs, attitudes, and practices concerning the SARS-CoV2 Omicron variant.

Variable	Frequency	Percentage
Vaccines are the most effective way to prevent the spread of the Omicron variant or other future variants		
Agree	860	66.9
Disagree	425	33.1
Universal masking is still effective in preventing the spread of the Omicron variant or other future variants		
Agree	999	77.8
Disagree	286	22.2
Social distancing is still effective in preventing the spread of the Omicron variant or other future variants		
Agree	1002	78.0
Disagree	283	22.0
Avoiding unnecessary international travel is still effective in preventing the spread of the Omicron variant or other future variants		
Agree	917	71.4
Disagree	368	28.6
The COVID-19 vaccine should be mandatory for all adult populations		
Agree	1056	82.2
Disagree	229	17.8
In view of the Omicron variant outbreak, what do you think is the best booster COVID-19 vaccine?		
Any of the current mRNA vaccines (Pfizer–BioNTech or Moderna COVID-19)	549	42.7
A new mRNA vaccine that is developed to better target the Omicron	346	26.9

variant		
Another, non-mRNA-type vaccine	53	4.1
It does not matter; I will be OK with receiving any vaccine as a third booster dose	337	26.2
Who is at the highest risk from the Omicron variant in your opinion?		
The elderly	894	14.9
Patients with diabetes	753	12.6
Patients with cardiovascular diseases such as hypertension	703	11.7
Patients with chronic renal disease	792	13.2
Patients with immune deficiency	1014	16.9
Healthcare workers	846	14.1
The obese population	607	10.1
The young population	335	5.6
Previously unvaccinated people (added from others)	18	0.3
Others	36	0.6
The Omicron variant has the potential to cause a new COVID-19 pandemic wave worldwide.		
Agree	741	57.7
Disagree	544	42.3
The Omicron variant may cause another COVID-19 wave in Saudi Arabia.		
Agree	590	45.9
Disagree	695	54.1
A second national lockdown may be implemented if an Omicron variant outbreak occurs.		
Agree	593	46.2
Disagree	692	53.8
Using a Likert rating from 1-5, how worried are you by		
International travel *		3.19 (1.12)
The original variant that started the first pandemic *		1.96 (1.14)
The Alpha variant (which was first described in the UK) *		1.67 (1.1)
The Delta variant (which was first described in India) *		1.97 (1.13)
The new Omicron variant *		2.18 (1.14)

242 * Mean (SD)

243

244 **HCWs' perceptions of vaccination and other preventive measures to prevent the spread of**
245 **SARS-CoV-2 variants**

246 The HCWs' belief in universal masking, social distancing, and avoiding unnecessary
247 international flights to prevent the spread of SARS-CoV-2 variants correlated strongly and
248 significantly with their belief that vaccines are still the most effective way to prevent the spread of
249 Omicron and other future variants ($r = 0.707, 0.675, 0.603$, respectively; $p < 0.01$). Their mean worry
250 level in relation to international travel also correlated significantly with the above measures ($r =$

251 0.102, 0.134, 0.157, respectively; $p < 0.01$), which also correlated with their agreement with COVID-19
 252 vaccine mandates for all adults ($r = 0.139$, $p < 0.01$). Their mean worry level in relation to the
 253 Omicron variant correlated significantly and strongly with their perception of the effectiveness of
 254 the above preventive measures, including vaccination to prevent its spread and mandatory
 255 vaccination ($r = 0.082, 0.103, 0.132, 0.160, 0.114$, respectively; $p < 0.01$). Self-rated familiarity with the
 256 Omicron or Delta variants correlated strongly and significantly only with their agreement of
 257 universal masking as a preventive measure to prevent the spread of other variants, including
 258 Omicron, ($r = 0.090, 0.094$, respectively; $p < 0.01$). Additionally, their familiarity with either variant
 259 correlated significantly with their agreement with mandatory vaccination ($r = 0.167, 0.142$,
 260 respectively; $p < 0.01$) (Table 5).

261

Table 5: Correlation between participants' perceptions about vaccines, universal masking and social distancing to prevent the spread of the Omicron variant.

Variable	Vaccines effectiveness ^a	Universal masking effectiveness ^b	Social distancing effectiveness ^c	COVID-19 vaccine mandate ^k
Universal masking ^d	.707**			
Social distancing effectiveness ^e	.675**	.889**		
Avoiding unnecessary international travel ^f	.603**	.755**	.794**	
Omicron variant potential/new COVID-19 pandemic ^g	-.002	.011	.017	
Omicron variant potential/COVID-19 wave ^h	.005	-.015	.000	
Omicron variant potential/lockdown ⁱ	.010	.027	.051	
COVID-19 vaccine mandate ^k	.179**	.117**	.113**	
Mean worry level in relation to international travel	.102**	.134**	.157**	
Mean worry level in relation to original variant	.069*	.091**	.111**	.139**
Mean worry level in	.065*	.075**	.098**	.148**

relation to Alpha variant				
Mean in relation to level from Delta variant	.069*	.109**	.124**	.114**
Participants' mean worry level in relation to the Omicron variant	.082**	.103**	.132**	.114**
Self-rated familiarity with Omicron variant	.090*	.055*	.069*	.167**
Self-rated familiarity with the Delta variant	.094**	.062*	.066*	.142**

262 a Vaccines are still the most effective way to prevent the spread of Omicron and other future
263 variants. b Universal masking is still effective in preventing variant spread. c Social distancing is
264 still effective in preventing variant spread. d Participants' agreement level with universal masking
265 still being effective in preventing the spread of SARS-CoV-2 variants. e Participants' agreement level
266 with the effectiveness of social distancing to prevent the spread of SARS-CoV-2 variants. f
267 Participants' agreement level with the effectiveness of avoiding unnecessary international travel to
268 prevent the spread of SARS-CoV-2 variants. g Participants' agreement level with the potential of the
269 Omicron variant to cause a new COVID-19 pandemic wave worldwide. h Participants' agreement
270 level with the potential of the Omicron variant to cause another COVID-19 wave in Saudi Arabia. i
271 Participants' agreement level with the potential of the Omicron variant to cause second lockdown. k
272 Participants' agreement level with COVID-19 vaccine mandates.


273 **. Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level
274 (2-tailed). Note: Correlation (r) coefficients <0.10 are considered non-significant or are weak even if
275 their p values are <0.050.

276

277 Multivariate logistic regression analysis of multi-variables related to the HCWs and their
278 perception of the ineffectiveness of the currently available COVID-19 vaccines to prevent the spread
279 of SARS-CoV-2 variants found that the HCWs' age correlated positively with their agreement with
280 the ineffectiveness of the COVID-19 vaccines when they were aged over 35 years (OR = 1.25, p =
281 0.235), and significantly when they were aged 55 and above (OR = 1.96, p = 0.034) (Figure 1) (Table
282 6). HCWs who strongly believed that universal masking and avoiding unnecessary international
283 flights are still effective ways to prevent the spread of mutant variants were in significant
284 disagreement with the ineffectiveness of the vaccines to prevent the spread of current and future
285 mutant variants.

286 In addition, those who believed that COVID-19 vaccination should be mandatory for all
 287 adults or believed that mutant variants are an expected phenomenon also showed strong
 288 disagreement with the ineffectiveness of the vaccines. HCWs who worked in critical care areas
 289 showed significant agreement with the belief that the COVID-19 vaccines are ineffective in
 290 preventing the spread of mutant variants. Regarding the HCWs' sources of information, those who
 291 significantly relied on the WHO did not believe in the efficacy of the vaccines to prevent the spread
 292 of current or future mutant variants (Table 6).

293



294

295 Figure 1: Odds ratio between the participants' ages and their agreement with the
 296 ineffectiveness of the COVID-19 vaccines to prevent the spread of mutant variants; the
 297 correlation is significant for those over 55 years old; $p = 0.034$.

298 Table 6: Multivariate logistic regression analysis of odds of agreement with the ineffectiveness
 299 of the COVID-19 vaccines to prevent the spread of mutant variants, especially Omicron.

Variable	Multivariate adjusted odds ratio	95% C.I. for OR		p value
		Lower	Upper	
Sex =male	.857	.609	1.208	0.379

Age =35 to 44 years	1.255	.863	1.827	0.235
Age =45-54 years	1.502	.967	2.332	0.070
Age >=55 years	1.965	1.054	3.663	0.034
Work area =ICU	1.925	1.194	3.103	0.007
Work area = OR	2.148	.878	5.255	0.094
Previously diagnosed with COVID-19	1.292	.897	1.863	0.169
Does not want to take the COVID-19 vaccine	1.564	.833	2.937	0.164
Believes SARS-CoV-2 variants are expected	.799	.638	1.000	0.050
Believes universal masking is still effective at preventing the spread of variants	.318	.258	.393	<0.001
Believes avoiding unnecessary international travel is still effective at preventing the spread of variants	.617	.499	.763	<0.001
Agreement level that the Omicron variant has the potential to cause a new COVID-19 pandemic wave worldwide	1.208	.934	1.562	0.149
Agreement level that COVID-19 vaccination should be mandatory for all adults	.355	.263	.478	<0.001
Source of info: MOH website	.760	.544	1.062	0.108
Source of info: WHO website	1.474	1.046	2.077	0.027
Source of info: CDC website	.768	.521	1.133	0.183
Source of info: Scientific journals	.774	.526	1.137	0.191
Worry level in relation to the Delta variant	1.127	.971	1.307	0.117

Dependent variable: COVID-19 vaccine ineffectiveness to prevent the spread of mutant variants, especially Omicron.

300 An analysis of the characteristics of the surveyed HCWs found that males (compared to
 301 females) were in significant agreement with mandatory vaccination of all eligible adults, while age
 302 did not correlate with agreement with mandatory vaccination. HCWs who relied on social media as
 303 a source of information were in significant agreement with mandatory vaccination for all adults,
 304 self-rated familiarity level with the Omicron variant and the agreement that there could be further
 305 national lockdowns due to the Omicron variant. Furthermore, the level of agreement with the
 306 effectiveness of vaccines to prevent the spread of mutant variants correlated significantly with
 307 agreement with mandatory vaccination.

308 Those who were absolutely unwilling to receive the vaccine were five times more likely to
 309 disagree with mandatory vaccination, while those who agreed with the effectiveness of unnecessary
 310 travel avoidance to prevent the spread of mutant variants were 1.5 times more likely to disagree
 311 with the mandatory vaccination of all eligible adults (Table 7).

312 **Table 7: Multivariate logistic regression analysis of odds of disagreement with mandatory**
 313 **COVID-19 vaccination.**

Variable	Multivariate adjusted odds ratio	95% C.I. for OR		p value
		Lower	Upper	
Sex = male	.692	.487	.983	.040
Age group	.865	.723	1.035	.113
Nationality = expatriate	.295	.209	.416	<0.001
Absolute unwillingness to receive vaccines	5.661	3.303	9.704	<0.001
Reliance on social media as source of information	.614	.438	.860	.005
Reliance on MOH official statements as source of information	1.278	.914	1.788	.152
Self-rated familiarity level with Omicron variant	.754	.637	.893	.001
Agreement level with the effectiveness of vaccines to prevent the spread of variants	.525	.428	.644	<0.001
Agreement level with the effectiveness of unnecessary travel avoidance to prevent the spread of	1.438	1.188	1.740	<0.001

variants				
Agreement level with the possibility of a second national lockdown due to the Omicron variant	.580	.472	.714	<0.001

Dependent variable: disagreement with mandatory COVID-19 vaccination.

314

315

316 **Discussion**

317 This study explored HCWs' perceptions and awareness of the SARS-CoV-2 Omicron variant
318 after the initial WHO alert, in addition to their agreement with vaccine effectiveness to prevent its
319 spread or other potential future variants. Most (64%) respondents were female, similar to a
320 previous study about Delta variant concerns in KSA. This was also in agreement with other studies
321 showing that the majority of HCWs are female [25-27].

322 One-fifth of study participants received a booster dose, while the majority reported plans to
323 receive it once they became eligible, with a small percentage (6%) not planning to receive it. The
324 majority (69.6%) in our study chose to receive the booster dose with any of the currently available
325 mRNA vaccines or newly developed ones; this observation mirrors another study conducted in a
326 neighboring country among HCWs, where they also preferred mRNA vaccines[28]. Such behavior
327 could be partly due to the hematological side effects that have been recorded with the viral vector
328 vaccines [28]. In addition, this could signal vaccine selectivity (VS), which is currently an emerging
329 public health challenge due to the multiplicity of vaccine options. Another explanation is vaccine
330 hesitancy (VH), which could be related to reliance on social media as the main source of
331 information, which was reported by almost half of the participants, as opposed to less than
332 one-third who reported utilizing scientific journals as a main source of information; therefore,
333 increased access to peer-reviewed journals should be strongly encouraged among HCWs[25].
334 Keeping in mind the double edge sword effects the social media plays on individuals' decision
335 making, as social media spreads information that's not scientifically always verified, puts their
336 personal touch or psycho-cognitive flavor that drives the audience, therefore our observation of
337 social media being highly used source of information by the surveyed HCWs can explain some
338 observations like (VS), (VH) and HCWs significant agreement with mandatory vaccination for all
339 adults. Such agreement might be a reflection of their self-rated familiarity level with the Omicron
340 variant (stemming from the information they acquired from social media) that also correlated
341 significantly with their agreement with mandatory vaccination. Social media spread with the
342 emergence of the Omicron variant a huge load of information that was potentially driving all
343 sectors of the society to abide with all the measures of protection including vaccination, from
344 SARS-CoV-2 including its new Omicron variant.

345

346 The primary concerns regarding Omicron are whether it is more contagious, more virulent, or
347 both, in comparison to other variants, and how likely it would be to evade natural (post previous
348 COVID-19 infection) and vaccine-induced immunity [11,29-31]. However, with more than 30
349 mutations and some deletions that are similar to other variants, increased transmissibility and
350 higher antibody escape were expected [32]. However, with few clinical and epidemiological data to
351 help define the true threat of Omicron, participants' mixed knowledge responses are expected, as
352 has been observed in our study, in which they even extended to their belief in the effectiveness of
353 the vaccines to control its spread [33]

354 Among our study participants, regarding the perceived effectiveness of various methods to
355 control the spread of the Omicron variant, social distancing and universal masking scored the
356 highest, followed by avoiding international flights and, lastly, vaccination. Again, such
357 observations shed light on their questioning of the vaccine's effectiveness against Omicron due to
358 its many mutations, especially involving the spike protein. Their perceived effectiveness of the
359 current COVID-19 vaccines against the Omicron variant was 67%. This represents a decline in
360 HCWs' perception of vaccine efficacy compared to our earlier study, performed in December 2020
361 during the initial rollout of the COVID-19 vaccines, which was 80.2% [34]. Such findings reflect
362 declining confidence in vaccine efficacy against emerging variants, which is noteworthy since their
363 concerns about efficacy have been stated as one of the main reasons for vaccine hesitancy [35].
364 COVID-19 vaccine-related uncertainty and challenges persist in the face of combating emerging
365 SARS-CoV-2 variants. Immune escape is a real concern with the Omicron variant. According to
366 findings from South Africa, the efficacy of the Pfizer-BioNTech vaccine against the Omicron variant
367 was significantly reduced, with a 41-fold lower level of neutralizing antibodies when compared to
368 the wild-type variant of SARS-CoV-2 [10].

369
370 The fact that 82.2% of HCWs agree with mandatory COVID-19 vaccination for all adults is an
371 interesting finding. Mandating immunizations for HCWs or other business employees is not only
372 ethical, but also legal. Employers have the right to require vaccination as a condition of
373 employment, as the Equal Employment Opportunity Commission and courts have stated [36] and a
374 multi-society statement on COVID-19 vaccination had been also released [37]. This right applies to
375 both vaccinations approved for emergency use and those that have been fully approved by the FDA.
376 Mandates, however, can erode public support, causing a backlash and even lowering vaccine
377 uptake. There are no established processes to enforce population-wide vaccination obligations in
378 most countries, despite the fact that employers, healthcare providers, and educational institutions
379 can monitor compliance with mandates. Requiring COVID-19 immunizations for HCWs, for
380 example, is not a new practice; rather, it is a continuation of a long-standing policy. Vaccination
381 against influenza, hepatitis B, and other infectious diseases has long been mandatory in many
382 health-care settings [38]. Whether to mandate COVID-19 vaccination for HCWs and/or all
383 employees and how to implement such a policy is ultimately a local authority decision. For instance,
384 the local authorities in both New York and California announced a vaccine mandate for state
385 employees [39].

386
387 We observed that HCWs' beliefs in infection control measures that have been mandated and
388 optimized during the COVID-19 pandemic namely, universal masking, social distancing, and
389 vaccination as preventive methods for the spread of the Omicron variant or other future variants
390 [40,41] all correlated positively and significantly with their belief in mandatory vaccination for all

391 eligible adults. They still believed that avoiding unnecessary international travel is an effective
392 measure in preventing the spread of SARS-CoV-2 variants, even after widespread vaccination,
393 perhaps due to the emergence of at least three variants, one of them with high transmissibility and
394 serious clinical morbidity and high mortality (the Delta variant). However, there is a huge
395 consequence of travel ban and lockdown with any emerging variant[42,43].

396 HCWs who believed that SARS-CoV-2 mutations are expected and will reoccur were
397 significantly less in agreement with the belief that the vaccines are ineffective against the spread of
398 the Omicron variant or other potential future variants, which is an expected and healthy belief, as
399 the best preventive measure to contain the pandemic at present is widespread vaccination This has
400 been observed in HCWs' stringent behavior of abiding by the infection prevention measures, such
401 as universal masking and social distancing, for the same purpose [40,41], which has also been
402 observed in our results, in which agreement with the effectiveness of vaccination to prevent the
403 spread of mutant variants is significantly and positively associated with agreement with mandatory
404 vaccination.

405

406 HCWs in critical care areas believed significantly in the ineffectiveness of the vaccines to prevent
407 the spread of mutant variants, including Omicron. This might be explained by the multiple
408 mutations that the Omicron variant has and the critical care workers' anxiety regarding the current
409 vaccine's efficacy against it, being frontliners exposed to severe cases. In the same vein, we
410 observed that HCWs who relied on the WHO as a main source of information disagreed with the
411 vaccine's effectiveness to prevent the spread of the mutant strains, including Omicron, as it is a
412 scientific source that releases only evidence-based information, which has not thus far proven the
413 vaccine's efficacy in that regard.

414 Male gender was significantly associated with agreement with mandatory vaccination of all
415 eligible adults. This attitude has been observed in multiple studies, as males were more inclined
416 toward vaccine uptake and had much less vaccine hesitancy, while age did not correlate with
417 mandatory vaccination agreement [28,44].

418 The level of agreement with the effectiveness of vaccines to prevent the spread of mutant
419 variants was significantly associated with agreement with mandatory vaccination, and the same
420 was observed with the level of agreement with the belief that there might be a second national
421 lockdown due to the Omicron variant. This behavior from HCWs—of stringent abidance with
422 vaccination—correlates with their expectation of its effectiveness to prevent the spread of any
423 mutant variant, and their fear of a national lockdown, not unexpectedly, drove them to have an
424 unwavering belief in mandatory vaccination as the best modality to prevent it. However, they did
425 not perceive the effectiveness of unnecessary travel avoidance to be effective in preventing the
426 spread of mutant variants or being superior to mandatory vaccination. Early lockdown and social
427 distancing in the initial phase of the pandemic were useful in slowing the spread of SARS-CoV-2 in
428 Saudi Arabia[45]. In addition, during the peak of the initial lockdown the level of anxiety was
429 associated with being with family members at risk of SARS-CoV-2 infection. Thus, it is
430 understandable that HCWs fear the occurrence of second lockdown with the emergence of the
431 Omicron variant[46].

3.1 Study limitations and strengths

While this research is subject to the limitations of cross-sectional studies, such as sampling, response rate, and uneven geographical representation, the fact that we carried out the study early on in the spread of the Omicron variant also limited our ability to assess the awareness of the HCWs in relation to the variant, especially given the scarce scientific data available after it was first identified. Despite this, the scientific evidence regarding the current vaccines' effectiveness against the Omicron variant will take a significant amount of time to materialize. As with the evolving situation in regard to variants, HCWs' experiences and perceptions are also likely to change. Moreover, HCWs' experiences may differ from one setting to another.

4. Conclusion

This is the first national survey in Saudi Arabia that was conducted in the first week of the WHO Omicron variant announcement, to address HCWs' awareness of the variant, acceptance of vaccine booster doses and agreement with vaccination to prevent the spread of SARS-CoV-2 Omicron variant or future variants. Only about two-thirds of HCWs perceived that vaccination is the best option to prevent the spread of the Omicron variant, indicating the need for future studies to explore the performance of currently available vaccines in terms of the protection they offer against the current variants. At the same time, the HCWs had a strong belief in preventive measures, such as universal masking and social distancing, to prevent the spread of Omicron or future variants, which should still be maintained in practice, at least in healthcare institutions, to prevent nosocomial spread until further evidence can be elucidated.

Abbreviations:

CDC: Center for Disease Control and Prevention

COVID-19: Coronavirus disease 2019

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

WHO: World Health Organization

Conflicts of interest: None declared.

Ethics approval and consent to participate: The study was approved by the institutional review board of King Saud University (approval 21/01039/IRB).

Acknowledgments: This research has been financially supported by Prince Abdullah Ben Khalid Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University, Riyadh, Kingdom of Saudi Arabia. The research team is thankful for the statistical data analysis consultation offered by www.hodhoddata.com.

Author contributions: M.H.T., S. Alenezi, M.A., F.A., K.A., F.A., S. Al-Subaie, M.B., Z.M., and J.A. conceptualized the study, analyzed the data, and wrote the manuscript. R.A., R.B., F.A., A. Arabiaah, A. Alhaboob, A. Alaraj, N.S.A., R.H., L.A., N.A., A.J., A. Aleyadhy, and W.A. contributed to the study design; collected, analyzed, interpreted data; and edited the manuscript.

All authors reviewed and approved the final version of the manuscript.

References

1. World Health Organization, Classification of Omicron (B. 1.1. 529): SARS-CoV-2 variant of concern. *November 2021*, 26, 2021.

- 473 2. Volz, E.; Mishra, S.; Chand, M.; Barrett, J.C.; Johnson, R.; Geidelberg, L.; Hinsley, W.R.;
474 Laydon, D.J.; Dabrera, G.; O'Toole, Á.; et al. Assessing transmissibility of SARS-CoV-2
475 lineage B.1.1.7 in England. *Nature* **2021**, *593*, 266-269, doi:10.1038/s41586-021-03470-x.
- 476 3. Chen, J.; Wang, R.; Gilby, N.B.; Wei, G.-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine
477 Breakthrough, and Antibody Resistance. *Journal of Chemical Information and Modeling* **2022**,
478 *62*, 412-422, doi:10.1021/acs.jcim.1c01451.
- 479 4. Al-Tawfiq, J.A.; Hoang, V.T.; Le Bui, N.; Chu, D.T.; Memish, Z.A. The Emergence of the
480 Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?
481 In *J Epidemiol Glob Health*; 2022; pp. 1-4.
- 482 5. WHO. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for
483 Member States. Available online:
484 [https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-tech-](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
485 [nical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states) (accessed on 25 Dec 2021).
- 486 6. Ren, S.Y.; Wang, W.B.; Gao, R.D.; Zhou, A.M. Omicron variant (B.1.1.529) of SARS-CoV-2:
487 Mutation, infectivity, transmission, and vaccine resistance. *World J Clin Cases* **2022**, *10*, 1-11,
488 doi:10.12998/wjcc.v10.i1.1.
- 489 7. Yang, W.; Shaman, J. SARS-CoV-2 transmission dynamics in South Africa and
490 epidemiological characteristics of the Omicron variant. *medRxiv* **2021**,
491 doi:10.1101/2021.12.19.21268073.
- 492 8. TheGuardians. Omicron: everything you need to know about new Covid variant. Available
493 online:
494 [https://www.theguardian.com/world/2021/nov/26/vaccine-resistant-what-scientists-know-n-](https://www.theguardian.com/world/2021/nov/26/vaccine-resistant-what-scientists-know-new-covid-variant)
495 [ew-covid-variant](https://www.theguardian.com/world/2021/nov/26/vaccine-resistant-what-scientists-know-new-covid-variant) (accessed on 18 Dec 2021).
- 496 9. Torjesen, I. Covid-19: Omicron may be more transmissible than other variants and partly
497 resistant to existing vaccines, scientists fear. *Bmj* **2021**, *375*, n2943, doi:10.1136/bmj.n2943.
- 498 10. Cele, S.; Jackson, L.; Khan, K.; Khoury, D.S.; Moyo-Gwete, T.; Tegally, H.; Scheepers, C.;
499 Amoako, D.; Karim, F.; Bernstein, M.; et al. SARS-CoV-2 Omicron has extensive but
500 incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for
501 infection. *medRxiv* **2021**, doi:10.1101/2021.12.08.21267417.
- 502 11. Chen, J.; Wang, R.; Gilby, N.B.; Wei, G.W. Omicron Variant (B.1.1.529): Infectivity, Vaccine
503 Breakthrough, and Antibody Resistance. *J Chem Inf Model* **2022**, *62*, 412-422,
504 doi:10.1021/acs.jcim.1c01451.
- 505 12. Garcia-Beltran, W.F.; St Denis, K.J.; Hoelzemer, A.; Lam, E.C.; Nitido, A.D.; Sheehan, M.L.;
506 Berrios, C.; Ofoman, O.; Chang, C.C.; Hauser, B.M.; et al. mRNA-based COVID-19 vaccine
507 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* **2022**, *185*,
508 457-466.e454, doi:10.1016/j.cell.2021.12.033.
- 509 13. Danza, P.; Koo, T.H.; Haddix, M.; Fisher, R.; Traub, E.; K, O.Y.; Balter, S. SARS-CoV-2
510 Infection and Hospitalization Among Adults Aged ≥ 18 Years, by Vaccination Status, Before
511 and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County,
512 California, November 7, 2021-January 8, 2022. *MMWR Morb Mortal Wkly Rep* **2022**, *71*,
513 177-181, doi:10.15585/mmwr.mm7105e1.

- 514 14. Al-Tawfiq, J.A.; Al-Yami, S.S.; Rigamonti, D. Changes in healthcare managing COVID and
515 non-COVID-19 patients during the pandemic: striking the balance. *Diagn Microbiol Infect Dis*
516 **2020**, *98*, 115147, doi:10.1016/j.diagmicrobio.2020.115147.
- 517 15. Rigamonti, D.; Leonardi, R.; Al-Tawfiq, J.A. Coronavirus Disease Mortality: Understanding
518 Regional Differences. *Erciyes Medical Journal* **2022**, 3-7.
- 519 16. Temsah, M.H.; Al Huzaimi, A.; Alrabiaah, A.; Alamro, N.; Al-Sohime, F.; Al-Eyadhy, A.;
520 Alhasan, K.; Kari, J.A.; Alhaboob, A.; Alsalmi, A.; et al. Changes in healthcare workers'
521 knowledge, attitudes, practices, and stress during the COVID-19 pandemic. *Medicine*
522 (*Baltimore*) **2021**, *100*, e25825, doi:10.1097/md.00000000000025825.
- 523 17. Lasalvia, A.; Bodini, L.; Amaddeo, F.; Porru, S.; Carta, A.; Poli, R.; Bonetto, C. The Sustained
524 Psychological Impact of the COVID-19 Pandemic on Health Care Workers One Year after
525 the Outbreak-A Repeated Cross-Sectional Survey in a Tertiary Hospital of North-East Italy.
526 *Int J Environ Res Public Health* **2021**, *18*, doi:10.3390/ijerph182413374.
- 527 18. Mohapatra, R.K.; Tiwari, R.; Sarangi, A.K.; Islam, D.R.; Chakraborty, C.; Dhama, K.
528 COMMENTARYOmicron (B.1.1.529) variant of SARS-CoV-2- Concerns, challenges and
529 recent updates. *J Med Virol* **2022**, doi:10.1002/jmv.27633.
- 530 19. Khandia, R.; Singhal, S.; Alqahtani, T.; Kamal, M.A.; El-Shall, N.A.; Nainu, F.; Desingu, P.A.;
531 Dhama, K. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high
532 global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.
533 *Environ Res* **2022**, *209*, 112816, doi:10.1016/j.envres.2022.112816.
- 534 20. SPA. Health Ministry: Detecting Omicron Variant Case of Coronavirus in Saudi Arabia for
535 Citizen Coming Back from North African Country. Available online:
536 www.spa.gov.sa/2308747 (accessed on
- 537 21. Temsah, M.-H.; Alenezi, S.; Alarabi, M.; Aljamaan, F.; Alhasan, K.; Assiri, R.; Bassrawi, R.;
538 Alshahrani, F.; Alhaboob, A.; Alaraj, A.; Alharbi, N.S.; Alrabiaah, A.; Halwani, R.; Jamal, A.;
539 Abdulmajeed, N.; Alfarra, L.; Almashdali, W.; Al-Eyadhy, A.; AlZamil, F.; Alsubaie, S.;
540 Barry, M.; Memish, Z.A.; Al-Tawfiq, J.A. Healthcare Workers' SARS-CoV-2 Omicron Variant
541 Uncertainty-Related Stress, Resilience, and Coping Strategies during the First Week of the
542 World Health Organization's Alert. *Int. J. Environ. Res. Public Health* **2022**, *19*, 1944.
543 <https://doi.org/10.3390/ijerph19041944>
- 544 22. Temsah, M.H.; Alhuzaimi, A.N.; Alamro, N.; Alrabiaah, A.; Al-Sohime, F.; Alhasan, K.; Kari,
545 J.A.; Almaghlouth, I.; Aljamaan, F.; Al Amri, M.; et al. Knowledge, Attitudes, and Practices
546 of Healthcare Workers During the Early COVID-19 Pandemic in a Main, Academic Tertiary
547 Care Centre in Saudi Arabia. *Epidemiol Infect* **2020**, 1-29, doi:10.1017/S0950268820001958.
- 548 23. Temsah, M.H.; Al-Sohime, F.; Alamro, N.; Al-Eyadhy, A.; Al-Hasan, K.; Jamal, A.;
549 Al-Maglouth, I.; Aljamaan, F.; Al Amri, M.; Barry, M.; et al. The psychological impact of
550 COVID-19 pandemic on health care workers in a MERS-CoV endemic country. *J Infect Public*
551 *Health* **2020**, *13*, 877-882, doi:10.1016/j.jiph.2020.05.021.
- 552 24. Barry, M.; Temsah, M.H.; Aljamaan, F.; Saddik, B.; Al-Eyadhy, A.; Alenezi, S.; Alamro, N.;
553 Alhuzaimi, A.N.; Alhaboob, A.; Alhasan, K.; et al. COVID-19 vaccine uptake among
554 healthcare workers in the fourth country to authorize BNT162b2 during the first month of
555 rollout. *Vaccine* **2021**, doi:10.1016/j.vaccine.2021.08.083.

- 556 25. Temsah, M.H.; Barry, M.; Aljamaan, F.; Alhuzaimi, A.N.; Al-Eyadhy, A.; Saddik, B.;
557 Alsohime, F.; Alhaboob, A.; Alhasan, K.; Alaraj, A.; et al. SARS-CoV-2 B.1.1.7 UK Variant of
558 Concern Lineage-Related Perceptions, COVID-19 Vaccine Acceptance and Travel Worry
559 Among Healthcare Workers. *Front Public Health* **2021**, *9*, 686958,
560 doi:10.3389/fpubh.2021.686958.
- 561 26. Rabinowitz, L.G.; Rabinowitz, D.G. Women on the Frontline: A Changed Workforce and the
562 Fight Against COVID-19. *Acad Med* **2021**, *96*, 808-812, doi:10.1097/acm.0000000000004011.
- 563 27. Alhasan, K.; Aljamaan, F.; Temsah, M.H.; Alshahrani, F.; Bassrawi, R.; Alhaboob, A.; Assiri,
564 R.; Alenezi, S.; Alaraj, A.; Alhomoudi, R.I.; et al. COVID-19 Delta Variant: Perceptions,
565 Worries, and Vaccine-Booster Acceptability among Healthcare Workers. *Healthcare (Basel)*
566 **2021**, *9*, doi:10.3390/healthcare9111566.
- 567 28. Al-Sanafi, M.; Sallam, M. Psychological Determinants of COVID-19 Vaccine Acceptance
568 among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine
569 Conspiracy Beliefs Scales. *Vaccines (Basel)* **2021**, *9*, doi:10.3390/vaccines9070701.
- 570 29. Karim, S.S.A.; Karim, Q.A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19
571 pandemic. *Lancet* **2021**, *398*, 2126-2128, doi:10.1016/s0140-6736(21)02758-6.
- 572 30. Araf, Y.; Akter, F.; Tang, Y.D.; Fatemi, R.; Parvez, M.S.A.; Zheng, C.; Hossain, M.G. Omicron
573 variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19
574 vaccines. *J Med Virol* **2022**, doi:10.1002/jmv.27588.
- 575 31. Cele, S.; Jackson, L.; Houry, D.S.; Khan, K.; Moyo-Gwete, T.; Tegally, H.; San, J.E.; Cromer,
576 D.; Scheepers, C.; Amoako, D.G.; et al. Omicron extensively but incompletely escapes Pfizer
577 BNT162b2 neutralization. *Nature* **2021**, doi:10.1038/s41586-021-04387-1.
- 578 32. Greaney, A.J.; Starr, T.N.; Gilchuk, P.; Zost, S.J.; Binshtein, E.; Loes, A.N.; Hilton, S.K.;
579 Huddleston, J.; Eguia, R.; Crawford, K.H.D.; et al. Complete Mapping of Mutations to the
580 SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host*
581 *Microbe* **2021**, *29*, 44-57.e49, doi:10.1016/j.chom.2020.11.007.
- 582 33. Ferré, V.M.; Peiffer-Smadja, N.; Visseaux, B.; Descamps, D.; Ghosn, J.; Charpentier, C.
583 Omicron SARS-CoV-2 variant: What we know and what we don't. *Anaesth Crit Care Pain*
584 *Med* **2021**, *41*, 100998, doi:10.1016/j.accpm.2021.100998.
- 585 34. Barry, M.; Temsah, M.H.; Alhuzaimi, A.; Alamro, N.; Al-Eyadhy, A.; Aljamaan, F.; Saddik,
586 B.; Alhaboob, A.; Alsohime, F.; Alhasan, K.; et al. COVID-19 vaccine confidence and
587 hesitancy among health care workers: A cross-sectional survey from a MERS-CoV
588 experienced nation. *PLoS One* **2021**, *16*, e0244415, doi:10.1371/journal.pone.0244415.
- 589 35. Li, M.; Luo, Y.; Watson, R.; Zheng, Y.; Ren, J.; Tang, J.; Chen, Y. Healthcare workers' (HCWs)
590 attitudes and related factors towards COVID-19 vaccination: a rapid systematic review.
591 *Postgrad Med J* **2021**, doi:10.1136/postgradmedj-2021-140195.
- 592 36. EEOC. EEOC Issues Updated COVID-19 Technical Assistance. Available online:
593 <https://www.eeoc.gov/newsroom/eeoc-issues-updated-covid-19-technical-assistance>
594 (accessed on 27 Dec 2021).
- 595 37. Weber, D.J.; Al-Tawfiq, J.A.; Babcock, H.M.; Bryant, K.; Drees, M.; Elshaboury, R.; Essick, K.;
596 Fakhri, M.; Henderson, D.K.; Javaid, W.; et al. Multisociety statement on coronavirus disease
597 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel. *Infect*
598 *Control Hosp Epidemiol* **2021**, *1-9*, doi:10.1017/ice.2021.322.

- 599 38. Klompas, M.; Pearson, M.; Morris, C. The Case for Mandating COVID-19 Vaccines for
600 Health Care Workers. *Ann Intern Med* **2021**, *174*, 1305-1307, doi:10.7326/m21-2366.
- 601 39. Olick, R.S.; Shaw, J.; Yang, Y.T. Ethical Issues in Mandating COVID-19 Vaccination for
602 Health Care Personnel. *Mayo Clin Proc* **2021**, *96*, 2958-2962, doi:10.1016/j.mayocp.2021.10.020.
- 603 40. Al-Metwali, B.Z.; Al-Jumaili, A.A.; Al-Alag, Z.A.; Sorofman, B. Exploring the acceptance of
604 COVID-19 vaccine among healthcare workers and general population using health belief
605 model. *J Eval Clin Pract* **2021**, *27*, 1112-1122, doi:10.1111/jep.13581.
- 606 41. O'Donohue, L.S.; Fletcher-Gutowski, S.; Sidhu, A.; Verma, A.; Phillips, T.C.; Misra, P.G.
607 Mask use among health care workers and feelings of safety at work pre- and post-
608 COVID-19 vaccine. *Am J Infect Control* **2021**, doi:10.1016/j.ajic.2021.11.009.
- 609 42. Singhal, T. The Emergence of Omicron: Challenging Times Are Here Again! *Indian J Pediatr*
610 **2022**, 1-7, doi:10.1007/s12098-022-04077-4.
- 611 43. Mallapaty, S. Omicron-variant border bans ignore the evidence, say scientists. In *Nature*;
612 England, 2021; Volume 600, p. 199.
- 613 44. Maraqa, B.; Nazzal, Z.; Rabi, R.; Sarhan, N.; Al-Shakhra, K.; Al-Kaila, M. COVID-19 vaccine
614 hesitancy among health care workers in Palestine: A call for action. *Prev Med* **2021**, *149*,
615 106618, doi:10.1016/j.ypmed.2021.106618.
- 616 45. Ahmad Alajlan, S.; Alhusseini, N.K.; Mohammed Basheeruddin Asdaq, S.; Mohzari, Y.;
617 Alamer, A.; Alrashed, A.A.; Alamri, A.S.; Alsanie, W.F.; Alhomrani, M. The impact of
618 lockdown strategies on the basic reproductive number of coronavirus (COVID-19) cases in
619 Saudi Arabia. *Saudi J Biol Sci* **2021**, *28*, 4926-4930, doi:10.1016/j.sjbs.2021.06.047.
- 620 46. Albagmi, F.M.; AlNujaidi, H.Y.; Al Shawan, D.S. Anxiety Levels Amid the COVID-19
621 Lockdown in Saudi Arabia. *Int J Gen Med* **2021**, *14*, 2161-2170, doi:10.2147/ijgm.s312465.
- 622